Aldena Therapeutics and Empa Awarded InnoSuisse Funding to Advance STAR Particles as a Novel Drug Delivery Technology for Dermatology

BOSTON, April 26, 2023 /PRNewswire/ -- Aldena Therapeutics Inc. (Aldena), a private biotech company pioneering siRNA-based therapies for dermatological indications, and Empa, the Swiss Federal research institute for materials science and technology, have been awarded a joint 600'000 CHF grant by InnoSuisse, the Swiss Innovation Agency. This StarCURE grant seeks to co-develop microneedle particles as a new skin delivery system, which will enable novel therapeutic approaches in dermatology by revolutionizing the way drugs are delivered and absorbed through the skin.

This groundbreaking microneedle-particle technology, called STAR particles¹, now under exclusive license to Aldena was originally discovered and developed by Prof. Mark Prausnitz and Dr. Andrew Tadros at the Georgia Institute of Technology in Atlanta. These star-shaped ceramic microparticles enable delivery of large, water-soluble molecules into the skin at the site of application. Aldena Therapeutics is pioneering this technology as part of its portfolio of innovative dermatological programs.

The StarCURE collaboration between Aldena and Empa will be conducted over two years and will aim to establish a scalable manufacturing method for STAR particles and to investigate next-generation STAR particle materials that provide added capabilities.

Dr. Claire Bouix-Peter, Chief Operating Officer of Aldena Therapeutics and project coordinator, commented: "This project is a great opportunity to leverage our expertise in dermatology in collaboration with Empa's world-class materials and science experts to transform STAR particle manufacturing for commercial-scale production."

Prof. Prausnitz, co-Founder of Aldena Therapeutics, added: "This collaboration will enable the manufacturability and expanded functionality of STAR-particle technology, which is an essential and strategic next step in the development of Aldena."

Dr. Michael Stuer, Head of the Nanopowders and Ceramics Group at Empa's High Performance Ceramics lab, remarked: "This is a great example of how our expertise in ceramic materials can be applied to develop a safe and effective drug delivery technology."

Prof. Patrik Hoffmann, Head of the Laboratory for Advanced Materials Processing at Empa, added: "This is a very exciting project and I am confident that our joint research efforts will result in a scalable technology that could revolutionize the way skin drug delivery is viewed in the pharmaceutical industry, providing treatments with greater precision, efficiency, compliance and safety."

About Aldena

Aldena Therapeutics is a Boston, Lausanne and London-based biotechnology company focusing on siRNA-based dermatological treatments, enabled by STAR particles as a novel skin delivery system, for patients suffering from dermatological diseases. It was co-founded by Prof. John Harris (MD, PhD, Professor and Chair of Dermatology at UMass Chan Medical School), Prof. Mark Prausnitz (PhD, Regents' Professor at Georgia Institute of Technology) and Dr Andrew Tadros (MD, PhD), and is backed by Medicxi. Aldena Therapeutics is pursuing multiple innovative programs and is currently initiating the IND-enabling GLP nonclinical program for its lead projects.

About Empa

Empa, the Swiss Federal Laboratories for Materials Science and Technology, is an interdisciplinary Swiss research institute conducting cutting-edge materials and technology research, based in Dübendorf, St. Gallen and Thun, Switzerland. Empa aims at generating interdisciplinary solutions to major challenges faced by the industry, and at creating the necessary scientific basis to ensure that our society develops in a sustainable manner.

¹ Tadros, A et al., Nature Medicine 2020, v26, p341-347 https://doi.org/10.1038/s41591-020-0787-6

SOURCE Aldena Therapeutics

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED